特利加压素联合生长抑素治疗肝硬化食管胃底静脉曲张破裂出血疗效观察

doi:10.3969/j.issn.1672-5069.2015.04.024

Abstract

Wang Jun，Peng Hao. Observation of terlipressin and somatostatin in the treatment of patients with liver cirrhosis complicated by esophageal and gastric varices bleeding[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 418-419.

References

[1] Appenrodt B，Trebicka J，Sauerbruch T. Complications of liver cirrhosis. Dtsch Med Wochenschr，2011，136（31/32）:1601-1606.
[2] Brown MR，Jones G，Nash KL，et al. Antibiotic prophylaxis in variceal hemorrhage:timing，effectiveness and clostridium difficile rates. World J Gastroenterol，2010，16（42）:5317-5321.
[3] Sarin SK，Sharma P.Terlipressin：an asset for hepatologists. Hepatology，2011，54（2）:724-730.
[4] 郭莲怡，吕冬梅. 特利加压素治疗急性食管静脉曲张破裂出血临床研究. 重庆医学，2012，41（31）:3312-3313.
[5] 洪小飞，童秀萍，吴深宝，等. 特利加压素治疗食管胃底静脉曲张破裂出血39例. 医药导报，2014，33（2）:219-221.
[6] 彭微微，赵守松.肝硬化合并上消化道出血的综合治疗进展. 实用肝脏病杂志，2012，15（6）:594-596.
[7] 王吉耀. 肝硬化门脉高压食管胃静脉曲张出血的防治.实用肝脏病杂志，2013，16（3）:195-197.
[8] Wolin EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res，2012，5（5）:161-166.
[9] Mizutani G，Nakanishi Y，Watananbi N，et al. Expression of somatostatin receptor subtypes in neuroendocrine tumors using real-time RT-PCR method and immunohisochemistry.Acta Histochem Cytochem，2012，45（3）:167-172.
[10] 郭莲怡，王桂君. 生长抑素联合特利加压素治疗肝硬化急性食管静脉曲张破裂出血患者的临床观察.中国药房，2012，23（32）:2998-3000.
[11] 彭芸.特利加压素联合内镜静脉曲张套扎术预防急性食管静脉曲张破裂再出血的研究. 胃肠病学，2013，18（10）:613-614.
[12] 张鹰庆，卢园华，饶益娟. 特利加压素治疗食管静脉曲张出血临床疗效观察. 海峡药学，2012，24（12）:197-198.
[13] Tfiantos CK，Samonakis D，Thalheimer U，et al. Terlipress in therapy for renal failure in cirrhosis. Eur J Gastroenterol Hepatol，2010，22（1）:481-486.
[14] 李鹏，胡春娇，罗立强，等. 特利加压素治疗肝功能Child C级并上消化道出血效果观察. 中国乡村医药杂志，2014，21（9）:7-8.
[15] 朱丽琴.特利加压素治疗食管静脉曲张破裂出血的临床护理研究. 中国药业，2013，22（1）:59-60.
[16] 杨世达.特利加压素联合生长抑素治疗食管胃底静脉曲张破裂出血观察分析. 福建医药杂志，2014，36（3）:113-114.

Observation of terlipressin and somatostatin in the treatment of patients with liver cirrhosis complicated by esophageal and gastric varices bleeding

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[3]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[6]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[7]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[8]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[9]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[10]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[11]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[12]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[13]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[14]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[15]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.